암 유전자 치료 세계 시장 규모는 2023년 35억 달러로 평가되었습니다. 또한, 2024년 42억 5,000만 달러에서 2032년에는 200억 5,000만 달러로 성장하고, 예측 기간(2025-2032년) 동안 21.4%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.
세계 암 발병률 증가는 암 유전자 치료제 시장의 성장에 큰 영향을 미치고 있습니다. 주요 촉진요인으로는 혁신적인 암 치료에 대한 수요 증가, 유전공학 기술의 발전, 새로운 치료법 개발을 위한 대규모 투자 등을 들 수 있습니다. 기업들은 진행 중인 종양학 연구와 생존율 향상을 위한 맞춤형 치료 옵션에 대한 수요를 배경으로 새로운 유전자 치료제의 창출을 우선순위에 두고 있습니다. 또한, 암 환자들에 대한 정부의 지원은 치료 제공업체들에게 더 많은 기회를 제공합니다. 그러나 높은 치료 비용, 부작용 가능성, 제조상의 장애물 등의 문제는 시장의 장기적인 발전 가능성을 제한할 수 있습니다.
Global Cancer Gene Therapy Market size was valued at USD 3.5 billion in 2023 and is poised to grow from USD 4.25 billion in 2024 to USD 20.05 billion by 2032, growing at a CAGR of 21.4% during the forecast period (2025-2032).
The rising global incidence of cancer is significantly influencing the growth of the cancer gene therapy market. Key drivers include an increasing demand for innovative cancer treatments, advancements in genetic engineering technologies, and substantial investments directed towards the development of novel therapies. Companies are prioritizing the creation of new gene therapies fueled by ongoing research in oncology and the desire for personalized treatment options, which aim to enhance survival rates. Moreover, government support for cancer patients presents additional opportunities for therapy providers. However, challenges such as the high cost of treatments, the potential for adverse effects, and manufacturing hurdles could limit the market's long-term development potential.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Cancer Gene Therapy Market Segments Analysis
Global Cancer Gene Therapy Market is segmented by Type, Therapy, Product, End Use and region. Based on Type, the market is segmented into Ex-Vivo and In-Vivo. Based on Therapy, the market is segmented into Oncolytic Virotherapy, Gene-Induced Immunotherapy and Gene Transfer. Based on Product, the market is segmented into Viral Vectors, Non-Viral Vectors and Other Products. Based on End Use, the market is segmented into Biopharma Companies, Research Institutes and Other End-Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Cancer Gene Therapy Market
The Global Cancer Gene Therapy market is significantly propelled by advancements in genetic engineering and genome mapping technologies, which have seen substantial investments in gene research initiatives. These breakthroughs in genetics are increasingly converging with oncology research, leading to the development of innovative cancer gene therapies. This integration not only enhances treatment options but also stimulates market expansion, reflecting the growing importance of personalized medicine in addressing complex cancer challenges. As these technologies evolve, they are set to further accelerate the growth of the cancer gene therapy sector, ultimately striving to improve patient outcomes and revolutionize cancer treatment methodologies.
Restraints in the Global Cancer Gene Therapy Market
The Global Cancer Gene Therapy market faces significant restraints primarily due to the high costs associated with these advanced treatments. The expenses incurred from sophisticated equipment and thorough research and development processes make gene therapy inaccessible for many cancer patients. These financial barriers hinder the widespread adoption of cancer gene therapy, as not all patients can afford the treatment. Consequently, the high pricing remains a critical factor that limits the potential growth of the market, as cost-effective alternatives are often sought in the pursuit of effective cancer therapies. This economic limitation poses challenges for both patients and healthcare providers in accessing these innovative solutions.
Market Trends of the Global Cancer Gene Therapy Market
The Global Cancer Gene Therapy market is witnessing a significant trend toward the growing demand for combination therapies, driven by an increasing number of cancer patients seeking enhanced survival rates and improved treatment outcomes. This shift presents a strategic opportunity for cancer gene therapy providers to innovate and expand their offerings by developing novel combination therapies that synergistically leverage the effects of various treatment modalities, such as targeted therapies, immunotherapies, and traditional chemotherapies. By prioritizing research and collaboration, these providers can not only address the evolving needs of patients but also maximize their market potential and reinforce their competitive edge in the long-term landscape of oncology.